Novel α,β-unsaturated hydroxamic acid derivatives overcome Cisplatin (cas 15603-27-1) resistance

Add time:09/01/2019    Source:sciencedirect.com

A series of α,β-unsaturated hydroxamic acid derivatives as novel HDAC inhibitors (HDACi) with structural modifications of the connecting unit and the CAP group was synthesized. The in vitro evaluation against the human cancer cell lines A2780 and Cal27 identified 6e and 7j as the most potent compounds regarding HDAC inhibitory activity and inhibition of proliferation. Isoform profiling against HDAC2, 4, 6 and 8 revealed a preference for HDAC2 and 6 for both compounds in contrast to the pan HDACi panobinostat. 6e and 7j enhanced significantly Cisplatin (cas 15603-27-1)-induced cytotoxicity in a combination treatment mediated by increased apoptosis induction and caspase-3/7 activation. The interaction between 6e or 7j and cisplatin was highly synergistic and more pronounced for the cisplatin resistant subline Cal27CisR. IC50 values of cisplatin were even lower in Cal27CisR pretreated with 6e or 7j than for the parental cell line Cal27. Based on our findings, the novel dual class I/HDAC6 inhibitors could serve as an option to overcome cisplatin resistance with fewer side effects in comparison to panobinostat.

We also recommend Trading Suppliers and Manufacturers of Cisplatin (cas 15603-27-1). Pls Click Website Link as below: cas 15603-27-1 suppliers

Prev:Targeting STAT3 inhibition to reverse Cisplatin (cas 15603-27-1) resistance
Next:Oridonin elevates sensitivity of ovarian carcinoma cells to Cisplatin (cas 15603-27-1) via suppressing Cisplatin (cas 15603-27-1)-mediated autophagy)